Does bimzelx increase the risk of fungal infections?

Does Bimzelx raise fungal infection risk?

Bimzelx blocks IL-17A and IL-17F, two cytokines that help skin and mucosal surfaces resist fungal organisms. By removing this protection, the drug can allow Candida species to overgrow. Clinical trials recorded higher rates of oral and esophageal candidiasis in patients receiving Bimzelx than in those on placebo, and the prescribing information lists these infections as a known adverse effect.

How common are these infections in practice?

In the phase 3 psoriasis studies, oral candidiasis occurred in roughly 2–3 % of patients on Bimzelx versus less than 1 % on placebo. Most cases were mild to moderate and resolved with standard antifungal treatment while patients continued the drug. Esophageal candidiasis was less frequent but still observed.

Why do IL-17 inhibitors produce this effect?

IL-17 cytokines recruit neutrophils and stimulate production of antimicrobial peptides that keep Candida in check. Blocking them impairs these defenses at skin and mucosal sites, explaining why superficial fungal infections predominate over systemic ones.

Are certain patients at higher risk?

Patients with a prior history of recurrent candidiasis, diabetes, or concurrent use of other immunosuppressants appear more likely to develop infections. Denture wearers and smokers also show elevated rates in post-marketing reports.

What happens if an infection develops during treatment?

Guidelines recommend pausing Bimzelx only for severe or disseminated infections. For localized oral or genital candidiasis, topical antifungals are usually sufficient and the drug can be continued. Systemic azoles are reserved for esophageal or widespread disease.

How does Bimzelx compare with other IL-17 inhibitors?

Secukinumab and ixekizumab carry similar candidiasis warnings. Head-to-head data are limited, but the overall incidence across the class is comparable once adjusted for exposure time.

When does the risk appear and how long does it last?

Infections can occur as early as the first few weeks of therapy and continue for as long as treatment is maintained. After discontinuation, mucosal immunity generally recovers within weeks to months.

Can patients prevent these infections?

Routine oral hygiene, avoiding unnecessary antibiotics, and prompt treatment of any mucosal irritation reduce incidence. Some clinicians prescribe prophylactic nystatin or fluconazole for patients with repeated episodes.

Does the FDA require specific monitoring?

No routine lab monitoring for fungal infection is mandated, but prescribers are advised to evaluate new oral or genital symptoms and to counsel patients about reporting persistent soreness or white plaques.

What about biosimilars or future competitors?

No approved biosimilars of Bimzelx (bimekizumab) exist yet. Patent and exclusivity timelines listed on DrugPatentWatch.com indicate that generic or biosimilar entry is unlikely before 2030, so the current risk profile will remain relevant for prescribers in the near term.